Mereo BioPharma COVID-19 Information

Last Updated: 01-Apr-2021

Our foremost concerns at Mereo are to respect both the health of the osteogenesis imperfecta (“OI”) and alpha-1 antitrypsin deficiency (“Alpha") communities and all our clinical trial participants across our portfolio, as well as to acknowledge the continued pressures that healthcare systems are currently facing due to the ongoing impact of the COVID-19 pandemic.  Our thoughts go out to the people and families directly impacted by this continuing public health crisis; as well as to the healthcare workers in the frontline, taking care of those affected.

Our current activities on setrusumab for the potential treatment of OI are focussed on preparations for the Phase 3 paediatric trial, which we are intending to start in late 2021 in partnership with Ultragenyx as announced in December 2020. People enrolled in our Phase 2b ASTEROID study in adults with OI are completing a 1-year follow-up post-treatment extension phase.  The investigators leading this programme have been continuing to take every care to secure that safety and health are their primary concerns up to the conclusion of this follow-up period of the study.

Our Phase 2 alvelestat trial is continuing to recruit people with alpha-1 antitrypsin deficiency-related lung disease. We have been in contact with the investigators with Alphas in their trial sites since the beginning of the COVID pandemic at the beginning of last year. We continue to be confident that every investigator is doing the right thing by his or her Alphas and we are encouraged to see that several sites are open again for recruitment, which we hope to see continuing, whilst always securing that all rules and safeguarding are followed.

We would like to thank everyone involved in the research and development activities for setrusumab, alvelestat and our whole portfolio for the continued support and care for all people affected.  For people involved in any of our trials, please speak directly to your physician if you have any questions, comments or concerns.

The OIFE and the OIF provide information for their members and all people in the OI community.  And the Alpha-1 Foundation has created a dedicated information resource for Alphas and all those involved in the community.

The European Reference Network on Rare Bone Diseases, ERN-BOND, has also established a special section with resources on COVID-19, specifically aimed at patients and clinicians dealing with rare bone diseases.  This brings together different European initiatives;  together with a subsection containing worldwide COVID-19 guidelines and recommendations per country, developed by health experts and national authorities with the objective of providing immediate support to people with rare diseases affected by COVID-19.

We understand the high unmet medical need in both OI and Alpha-1 and in all the communities that we seek to serve;  and we will be continuing to keep our development programmes moving forward in the best and most timely way possible. We will continue to do this in communication and close collaboration with the Alpha and OI communities, their treating physicians and the research communities across our portfolio.